ArticleAging cell2014

Combined administration of testosterone plus an ornithine decarboxylase inhibitor as a selective prostate-sparing anabolic therapy.

Ravi Jasuja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.